** Shares of medtech firm Glaukos GKOS.N fall 11.2% to $139.7 premarket

** Co on Thursday posted Q4 net loss of $22.2 mln, vs Wall Street estimate of $20.8 mln loss, as per data compiled by LSEG

** GKOS reported Q4 revenue of $105.5 mln, vs est. of $100.7 mln

** Co forecast 2025 sales in the range of $475 million to $485 million compared with expectation of $479.8 mln

** GKOS's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve

** Stock has risen 75.7% in the past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))